Quick Takeaways
- Trails Edge Capital Partners, LP filed SCHEDULE 13G for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT).
- Disclosed ownership: 5.1%.
- Date of event: 23 Dec 2025.
Quoteable Key Fact
"Trails Edge Capital Partners, LP disclosed 5.1% ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT) on 23 Dec 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Trails Edge Capital Partners, LP | 5.1% | 6,145,198 | 6,145,198 | 0 | : Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai | Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC | |
| Trails Edge Biotechnology Master Fund, LP | 5.1% | 6,145,198 | 6,145,198 | 0 | Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai | Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC | |
| Ortav Yehudai | 5.1% | 6,145,198 | 6,145,198 | 0 | /s/ Ortav Yehudai | Ortav Yehudai / Individual |